The available report is connected directly to the listing.
Form / material film360° studio loop
Hyperreal material study08.1 sec / seamless
FORM / LOT RECORD
Linked before ordering.
- 01
- Identity
- 02
- Method
- 03
- Lot match
Weight Management
Available for research
Lot-documented reference material
GLP-3 (Retatrutide)
A lot-documented peptide reference material made for precise analytical work and straightforward recordkeeping.
99.34%
Reported purityCurrent lot DPS-7184415 · UPLC + mass spectrometry
View lot report →
$120
CoA available
One-time research orderNo subscription
Free U.S. shipping · Freeze-dried · CoA available
Lab-reported identityUPLC & mass spectrometry
Lot matchedCoA available
Freeze-driedReference material
Research onlyQualified buyers
01Material details
Review the identity, current reported result, methods, storage note, and document status in the material table below.
02Independent record
Open the independent report above to verify the values published on this page before placing a research order.
03Research-use requirements
For laboratory research only. Never for use in people or animals. Obtain and review the supplier-issued SDS before handling or storage.
04Potential human benefits
- Substantial weight-loss potentialTriple-receptor signaling pairs appetite reduction with pathways linked to energy expenditure. The phase 2 trial reported progressively greater weight loss through 48 weeks, reaching a 24.2% mean reduction in the 12 mg group.
- Appetite + glucose controlGLP-1 and GIP activity can reduce food intake and improve insulin response, while glucagon-receptor activity may add an energy-expenditure component to the overall metabolic effect.
- Liver fat + metabolic healthIn a phase 2 substudy, higher retatrutide doses produced large reductions in liver fat alongside improvements in body weight and several metabolic markers.
The Form standard
Built to be examined,
not assumed.
Every listing keeps the material, current record, and research boundary in one clear review path.
Review the stated analytical methods before ordering.
Presented as a laboratory reference material.
Research only. Never for use in people or animals.
Potential human relevance
Three metabolic pathways.
One unusually broad signal.
Retatrutide combines GIP, GLP-1, and glucagon receptor activity in one molecule. In a 48-week phase 2 obesity trial, the highest-dose group averaged 24.2% weight loss; a substudy also reported substantial reductions in liver fat. That breadth is why it has become one of the most closely watched metabolic peptides in development.
Substantial weight-loss potential
Triple-receptor signaling pairs appetite reduction with pathways linked to energy expenditure. The phase 2 trial reported progressively greater weight loss through 48 weeks, reaching a 24.2% mean reduction in the 12 mg group.
Appetite + glucose control
GLP-1 and GIP activity can reduce food intake and improve insulin response, while glucagon-receptor activity may add an energy-expenditure component to the overall metabolic effect.
Liver fat + metabolic health
In a phase 2 substudy, higher retatrutide doses produced large reductions in liver fat alongside improvements in body weight and several metabolic markers.
How the potential connects to the biology
Why it may matter
Coordinated GIP, GLP-1, and glucagon-receptor signaling.
What studies track
Receptor activation, cAMP response, and glucose-, lipid-, and energy-balance endpoints in controlled models.
How strong is the evidence?
Phase 2 randomized human trials of pharmaceutical retatrutide. Retatrutide remains investigational and is not FDA-approved.
What remains unknown: Retatrutide remains investigational, and cardiovascular-outcome benefit has not been established. Human trials used a specific pharmaceutical preparation, not this Form reference material.
Material details
The essentials.
Key identity and lot details from the current independent CoA.
| Product | GLP-3 (Retatrutide) |
|---|---|
| CAS number | 2381089-83-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | Approximately 4731 g/mol |
| Lot result | 99.34% purity; white lyophilized powder |
| Tested by | Horizon Analytical; lot DPS-7184415; UPLC and mass spectrometry |
| Storage | Not stated on the current lot CoA. Obtain and follow the supplier-issued SDS before handling or storage. |
| Lab records | Current lot CoA (PDF) · Request supplier-issued SDS |
SDS status: not currently posted. Request and review the supplier SDS before handling or storage; this page and CoA do not replace it.
Made for research
For in-vitro lab research, method development, and identity testing by qualified research customers.
Proof by lot
The available CoA is tied to this material and lot. Open it above or visit the CoA library.
Clear limits
For laboratory research only. Never for use in people or animals.
Before you order
By ordering, you confirm qualified research-only use.
